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Background: One of the major goals in cancer research is to find and evaluate the early presence of biomarkers in
human fluids and tissues. To resolve the complex cell heterogeneity of a tumor mass, it will be useful to
characterize the intricate biomolecular composition of tumor microenvironment (the so called cancer secretome),
validating secreted proteins as early biomarkers of cancer initiation and progression. This approach is not broadly
applicable because of the paucity of well validated and FDA-approved biomarkers and because most of the
candidate biomarkers are mainly organ-specific rather than tumor-specific. For these reasons, there is an urgent
need to identify and validate a panel of biomarker combinations for early detection of human tumors. This is
especially important for breast cancer, the cancer spread most worldwide among women. It is well known that
patients with early diagnosed breast cancer live longer, require less extensive treatment and fare better than
patients with more aggressive and/or advanced disease.
Results: In the frame of searching breast cancer biomarkers (especially using nipple aspirate fluid mirroring breast
microenvironment), studies have highlighted an optimal combination of well-known biomarkers: uPA + PAI-1 + TF.
When individually investigated they did not show perfect accuracy in predicting the presence of breast cancer,
whereas the triple combination has been demonstrated to be highly predictive of pre-cancer and/or cancerous
conditions, approaching 97-100% accuracy.
Conclusion: Despite the heterogeneous composition of breast cancer and the difficulties to find specific breast
cancer biomolecules, the noninvasive analysis of the nipple aspirate fluid secretome may significantly improve the
discovery of promising biomarkers, helping also the differentiation among benign and invasive breast diseases,
opening new frontiers in early oncoproteomics.Review
Breast tumour heterogeneity, cancer origin and
secretome biomarkers
Growing evidence suggests that human cancers develop
via a non-linear multi-step process of cellular diversifica-
tion and evolution. In particular, breast cancer initiation/
progression from ductal/lobular system are dynamic pro-
cesses of cell clonal adaptation to a fluctuating tumour
microenvironment [1]. During tumour expansion there is
a constant acquisition of genetic and epigenetic alter-
ations, increasing the intra-tumor heterogeneity, and mak-
ing difficult the development of effective therapies [2].* Correspondence: ferdinando.mannello@uniurb.it
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distribution, and reproduction in any mediumRecently, the classical hypothesis on the origin of hu-
man cancer known as clonal evolution (i.e., “reiterative
cycles of clonal expansion, genetic diversification and
clonal selection within the adaptive landscapes of tissue
ecosystems” [3]) has been revisited by the novel stem-
ming tumor evolution model, in which the continuous
clonal expansion of tumor cells is both triggered and
promoted by additional mutations and guided by Cancer
Stem Cells (CSC) (i.e., “able to evolve as a cancer grows
and repopulate the cancer when the bulk of the tumor is
wiped out by anticancer drugs” [4]).
About 150 years after Virchow’s original theory of can-
cer cell biology (“tumours as originating from immature
cells” [5]), and half a century after the introduction of
the term CSCs (“a rare subpopulation of multipotentntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the bulk cells” [6]), the effective existence of CSC has
been finally demonstrated for the first time in different
cancer models (e.g., intestinal [7], brain [8], and skin [9]
mouse tumors).
Through different technologically innovative bio-
molecular approaches, studies unequivocally demon-
strated the cellular heterogeneity of tumors, composed
of different set of cells (e.g., differentiated cancer cells,
cancer stem cells, non-cancer stem cells and non cancer
cells), hierarchically organized and characterized by spe-
cific biomolecular and morphological profiles.
It has been clearly demonstrated that cellular hetero-
geneity is closely related to stochastic transcriptional
events, leading to variations in patterns of expression
among genetically identical single cells [10]. This cell
heterogeneity provides a means for responding to the
continuing changes in the microenvironment. So, single
cells can easily take advantage of the inherent stochastic
variability in gene expression to increase their survival at
the expense of the rest of the clonal cell population [11].
Conventional cancer diagnostic tools (such as imaging
techniques, biopsies, etc.) are limited by the impossibility
to discern the intra-tumour cancer cells heterogeneity.
The low sensitivity and specificity of standard methods
to detect cancer cells or their specific secreted biomo-
lecules represent one of the major obstacle for cancer
diagnosis [10]. In fact, cancer cell heterogeneity may
limit (or at least mask) the detection of biomolecules
identified only from the averages of a large population of
cells, missing (or at least neglecting) molecules produced
only from rare cells (such as invasive/metastatizing can-
cer and/or cancer stem cells) [12].
Through the analytical technique of single-cell analysis
it is now possible to identify, quantify, isolate, and
characterize the heterogenous composition of a tumour
mass with single-cell resolution, with high efficiency of
cell viability and integrity for genomic, transcriptomic
and metabolomic analyses downstream [10]. This system
offers several advantages linked to the deeper compre-
hension of cellular and molecular composition of the
cancer mass, because of the possibility to highlight the
peculiarity of cellular morphology, whole-genome and
whole-gene expression profiles, etc. [13].
Besides the numerous differences detected among can-
cer cells within a tumour, cancer cell heterogeneity is
also actively guided by the surrounding stroma and the
components of the cancer microenvironment (e.g., con-
stitutive and criptic biomolecules). In this respect, both
cellular and non-cellular components (e.g., fibroblasts,
immunocytes as well as structural proteins and extracel-
lular compounds) may actively modulate the tumour
heterogeneity by exerting selective pressure on the
evolving tumour and by dictating the genetic/epigenetic/phenotypic composition of the tumour [14]. So, it be-
came crucial and urgent for biomolecular approaches to
find novel biomarkers to improve early detection, diag-
nosis, monitoring and treatment prediction. The metab-
olites released from both cancer and stromal cells are
essential part of the entire cancer secretome (mirroring
the tumor microenvironment) and represent a reservoir
of promising early and specific biomarkers detectable
firstly in cancer-related biological fluids (like pleural, as-
citic and breast fluids) and also circulating in blood as
surrogate biomarkers [15].
Unpromising and promising biomarkers to overcome
tumour heterogeneity
The documented natural occurrence of heterogeneity in
cancer cell populations within a tumor mass represents
the major obstacle for finding both an early predictive
biomarker and a successful therapeutic treatment [16].
A recent debate in the literature sheds light on the
use-misuse-disuse in laboratory and clinical medicine of
several cancer biomarkers, pointing out their difficulties
to reach the clinic, and the reasons of different failure-
success rates [17-20].
A biomarker (a little over 30 years old medical termin-
ology) represents an indicator of a peculiar biological
state that can objectively measure and compare normal
biological and pathogenetic processes, or pharmaco-
logical responses to a therapeutic intervention [21]. Ori-
ginating from tissues or body fluids, biomarkers may be
potentially used as a risk factor and/or a useful tool to
classify physio-pathologic conditions, to obtain basic in-
formations underlying the pathogenetic mechanism(s) of
human diseases, to detect cancers early, and to guide the
choice of therapy [22]. The impact of biomarkers in la-
boratory and clinical medicine (especially in clinical on-
cology) is crucial to improve diagnosis, prognosis and
treatment, in particular if the biomarker is detected be-
fore clinical symptoms or enables the monitoring of
drug response [23,24].
Despite the frenetic bio-medical progresses (more than
570,000 publications on PubMed using “biomarker(s)”
term, of which about 40% are “cancer biomarker”) and
the substantial advances in the understanding of the mo-
lecular and bio-cellular basis of human diseases [25], a
paucity of FDA-approved biomarkers is actually present
[20]. Moreover, despite the great number of protein bio-
markers described as promising candidates biomarkers,
only few have been pursued to support clinical medicine,
and most of them have unfortunately failed the valid-
ation studies [18,19].
The recent literature debate about cancer biomarkers
has focused attention to several crucial aspects and ca-
veats: a) complexity and underestimation of the problem,
b) missing data on cancer biology knowledge, c) funding
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ing discovery and scarce/neglected validation, f) pre-
analytical and methodological shortcomings, etc. [18-20].
Starting from the evidence that cancer represents a
cluster of multifaceted diseases involving alterations in
both biomolecular pathways and multiple gene expres-
sion (regulating stemness, cell growth, survival, escape
of immune surveillance, invasive and metastatic poten-
tial), the actual biological milestone of the cellular het-
erogeneity of tumors [4] represents the hardest obstacle
for finding “ideal” protein cancer biomarker(s). Although
a large number of candidate biomarkers have been indi-
vidually discovered, only few promising combinations of
them have been FDA-approved and are able to be trans-
lated into clinical practice [20].
A parallel effort is needed to characterize the hetero-
geneous composition of cancer cells and the influence of
cancer microenvironment at both biochemical and mo-
lecular level. It shall also be crucial to detect and validate
biomolecules as biomarkers, to provide diagnostic, prog-
nostic or predictive informations [24].
It seems clear that not only intracellular proteins (the
proteome), but also proteins secreted or shed into the
tumor microenvironment (the secretome) may play cru-
cial roles in driving the malignancy evolution of a tumor.
In fact, the proteome reflects both the post-translational
modifications and cellular pathways of a committed can-
cer cell; whereas improved secretome analyses provide
insights into the mechanisms of cancer cells, the biology
of tumor microenvironment, the cancer cell interactions
and tumor progression.
The analysis of the cancer secretome represents a very
promising approach able to detect cancer-related pro-
teins directly in body fluids mirroring the tissue-specific
tumor microenvironment, such as Nipple Aspirate Fluid
(NAF) for breast cancer [15,26].
In fact, the secretome of NAF samples (noninvasively
collected fluids from all breast cancer patients [27,28])
allow analysis of all the metabolites secreted by epithelial
and stromal cells lining the breast ductal/lobular tree,
representing the mirror breast microenvironment. The
NAF secretome would represent a great opportunity for
early diagnosis of breast cancer, limiting the decreased
tumour-specificity of surrogate breast cancer biomarkers
circulating in the blood.
Cancer biomarkers in breast microenvironment secretome
Breast cancer is one of the leading causes of death among
women around the world; due to its well known hetero-
geneity [29], encompassing multiple subgroups with differ-
ent molecular signatures, prognoses, and responses to
therapies, the exact molecular mechanisms underlying this
multifaceted disease has yet to be fully elucidated. To ob-
tain a significant reduction in morbidity and mortality infemale breast cancer the main tool is the significant im-
provement of both conventional diagnostic techniques
and laboratory methods to diagnose the disease earlier.
In fact, screening programs, digital mammography,
specialized care and the widespread use of therapeutic
agents, have reduced mortality rates but the identifica-
tion of molecular targets remains a primary long-term
goal for the development of specific early interventions
and individual therapeutic strategies [30].
More than 10 million people are diagnosed with can-
cer every year, and it is estimated there will be over 15
million new cases/year by 2020 [31]. In particular, breast
cancer (BC) is the most commonly diagnosed cancer
among women, and screening through mammography
and the early detection of disease has shown a signifi-
cant mortality reduction in clinical trials [32].
In the past decade, there have been considerable im-
provements in the way that human breast tumours are
identified and characterized, uncovering biomolecular
alterations by using different technologies (like DNA as-
sessment and mutation screening, gene-expression and
microRNA, proteomic-metabolomic-degradomic profil-
ing, etc.). In this respect, appropriate development of po-
tential early detection and diagnostic tests, especially in
the breast microenvironment, will be necessary prior to
their clinical application, with special attention to their
specificity and sensitivity to avoid over/under-diagnosis
and/or clinical misuse [26,27].
The relevant biological role of breast microenviron-
ment during cancer initiation and progression has been
widely and continuously analyzed but unfortunately up-
to-now not completely understood [33-35].
The microenvironment of the human mammary gland
is composed of epithelial cells surrounded by intricate
stroma (containing ECM components and various non-
breast cells like fibroblasts, endothelial cells, and leuko-
cytes). Through autocrine/paracrine mechanisms, physical
and hormonal interactions result which are crucial for
breast normal development and physiologic functions
[36,37]. However, it is well known that alterations in these
cell-cell and cell-matrix interactions (other than the
single-cell biomolecular and epigenetic changes) may lead
to the initiation and progression of BC [37,38].
Recently, the cell heterogeneity of a tumor mass and the
interactions between tumor and microenvironment have
been demonstrated (i.e., solid tumors are not masses of
equivalent cells, but instead contain cancer stem cells that
support tumor maintenance) [4,29]. Moreover, the com-
position of breast microenvironment may profoundly in-
fluence cellular phenotype, and drive tumor progression
affecting disease outcome through diverse susceptibility to
chemo-toxic insults [39,40].
The intraductal noninvasive approach of NAF secretome
analyses may provide a panel of candidate biomarkers
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on the breast microenvironment have shown that the pro-
liferation, survival, polarity, differentiation state, and inva-
sive capacity of breast cancer cells can be modulated by
myoepithelial and various stromal cells, mainly through
signal molecules (such as growth factors, cytokines, glycos-
aminoglycans, proteases, hormones, etc.) involved in cellu-
lar pathways and paracrine regulatory networks [26].
Structural, cellular, functional and genetic alterations
of stromal and epithelial cells may influence cell growth,
morphogenesis and plasticity and contribute to the de-
velopment of the tumorigenic phenotype [41].
Numerous studies have analyzed the expression of se-
lected candidate biomarkers (both genes and proteins)
in normal and neoplastic primary human breast tissues
[42], up-regulation of invasion and angiogenesis related
proteins and growth factors, may be involved in the
gradual break down of the basal membrane separating
epithelial and stromal cells [43,44].
These alterations can be monitored at the protein level
and the protein signatures in the breast cancer micro-
environment provide valuable information that may be
an aid to more effective diagnosis, prognosis, and re-
sponse to therapy, finally opening novel avenues for
cancer-related biomarker discovery [30,45].
Knowledge about the breast and breast cancer microen-
vironments [26,36,37] is fundamental to identify and dis-
cern the pathologically different BC phenotypes [29,46],
but also can help to perform personalized therapeutic
strategies improving prognosis [24,47,48].
Many studies have found candidate biomarkers for
early diagnosis and/or as possible reliable prognostic or
predictive parameters, but in some cases contradictory
results are reported [42,49]. The hot topic of cancer bio-
markers has been recently debated [17,19-21,24]; among
well-known biomarkers, uPA/PAI combination has long
been regarded as prognostic indicator of BC, widely con-
firmed by prospective, retrospective and meta-analysis
studies [49]. Nevertheless, uPA/PAI test has not been
widely adopted in clinical practice, mainly linked to the
fact that “Clinicians usually prefer to over-treat some BC
patients, instead of using prognostic biomarkers with less
than perfect prediction” [20].
The uPA-PAI system and the TF antigen
Among candidate biomarkers for human BC consider-
able attention has been focused recently on the combin-
ation of the Urokinase-dependent plasminogen activator
system (uPA), Plasinogen activator inhibitor (PAI) and
the Thomsen-Friedenreich antigen (TF).
The serine proteinase urokinase-type plasminogen ac-
tivator (uPA; EC 3.4.21.73) and its specific inhibitors
(the plasminogen activator inhibitor type-1 and −2, PAI-
1 and PAI-2, respectively), are involved in the control ofextracellular matrix turnover, tissue remodeling, cell ad-
hesion and migration during physiopathological pro-
cesses, including breast cancer [50,51].
Altered expression of the plasminogen activation sys-
tem (uPA-PAI-uPA receptor) was found to be correlated
with tumor malignancy. It is believed that the tissue
degradation following plasminogen activation facilitates
cancer cell invasion contributing to metastasis. Data ac-
cumulating over the past 20 years have shown that the
uPA system shows multifunctional roles in healthy and
neoplastic conditions [50]. In particular, the uPA system
may affect breast cancer cell growth and its invasive and
metastatic behavior (44); moreover, both uPA and PAI-1
have been associated with a poor prognosis in BC pa-
tients, predicting both outcome and response/resistance
to specific therapies [52,53].
To date, these molecules are the only prognostic markers
that have reached the highest level of evidence (LOE-1) in
multi-centered clinical trials [52]. Unfortunately, the clin-
ical utility of these molecules as biomarkers is limited to
use as a laboratory test for basic cancer tissue detection
and they are not yet used as prognostic tool [20,49].
The Thomsen–Friedenreich antigen (TF or CD 176),
represents O-linked mucin type glycan found in about
90% of all human cancer and defined since 1920’s as
pancarcinoma antigen [54,55].
Although the mechanism of increased TF expression
occurrence in cancer is still not completely understood,
its increasing expression on the cancer cell surface as
the disease progresses may be mainly related to an active
unmasking procedure linked to altered glycosylation
mechanisms [56].
Although TF antigen roles in cancer are not com-
pletely understood (mainly due to different glycosylation
patterns in different types of cancers), the pancarcinoma
expression may have clinical utility as a potential im-
munotherapy target, leaving a possible glimmer of hope
against recurrence of advanced BC [57].
Early BC detection: new candidate biomarker
combination on the horizon?
On the basis of the well known evidence that BC: 1)
arises from the epithelial cells lining the ductal/lobular
system, 2) is characterized by elevated cell heterogeneity,
and 3) there is not currently a validated and FDA-
approved BC combination of biomarkers; the secretome
analyses of NAF fluids (as the mirror of the metabolic
pathways and cellular modifications occurring in the
breast microenvironment, both in physiological and
pathological conditions [26]) may reveal early signs of
precancerous and cancer transformation [27,58].
Starting from the first evidence of the clinical utility of
NAF analyses dating back to 1950s [59], growing evi-
dence has demonstrated and confirmed that this breast
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diagnosis or risk assessment of BC [60,61]. All these
studies have highlighted NAF as the optimal mirror of
the breast microenvironment, in which ductal/lobular/
stromal cell products, protein and hormonal components
are secreted and/or accumulated during physio-pathologic
conditions [27,28]. Also, among the wide number of
bio-compounds present in NAF, proteinase analyses have
gained increasing attention due to their role in the de-
gradative balance into breast microenvironment at the
tumor-host interface [62,63].
NAF samples thus represent the reservoir of biochem-
ical and hormonal components secreted by the ductal
tree appearing as the mirror of all metabolic changes oc-
curring within the breast gland; whereas, plasma samples
represent only the surrogate source which reflects only
in part the tissue-specific metabolic changes. On these
basis, the “intraductal approach” of the NAF secretome
is more accurate, specific and timely for early breast can-
cer detection [64].
Due to the ever growing interest of molecular medicine
moving from genomics to proteomics and metabolomics,
the secretome of NAF represents a suitable method to dis-
cover BC specific biomarkers. So, NAF fluids represent
protein-rich bioarchives highlighting what occurs within
the microenvironment of the breast ductal system during
all stages of the female breast life [61].
In the frame of searching cancer biomarkers in breast
microenvironment [26,27], a recent study published in
BMC Cancer [65] reports an interesting and innovative
combinatory analysis of three well-known predictive bio-
markers (uPA, PAI-1, and TF) in NAF collected noninva-
sively (or spontaneously secreted) from healthy women,
patients with breast atypia and cancer (in pre- and post-
menopause), requiring surgery because of a suspicious
breast lesions.
Some previous studies have demonstrated that TF
antigen was an independent predictor of disease only in
post-menopasual women, correctly classifying cancer
and atypia with a ROC value for disease prediction of
83% [66,67]. It has also been described that uPA system
(uPA, uPAR, and PAI) represent useful independent pre-
dictors of cancer presence, providing both diagnostic
and prognostic informations [68].
Although these biomolecules appeared individually not
perfectly accurate in predicting the presence of BC during
different menopausal status, Sauter’s research team demon-
strated the innovative biomarker combination in NAF [65]:
1) uPA concentration alone was more predictive of disease
in premenopausal women (AUC values 0.83-0.87); 2) the
range of AUC values for uPA+PAI-1 expression in all
women was 0.72-0.75; 3) TF antigen alone was better at
predicting BC in postmenopausal women showing range of
AUC values 0.81-0.83. While TF antigen + uPA expressionpredicted breast diseases in both pre- and post-menopausal
women with 84-92% of accuracy, interestingly and surpris-
ingly when TF uPA + PAI-1 were combined, the predictive
ability approached 97-100% allowing the near absolute pre-
diction of both atypia or cancer disease in women requiring
surgery because of a suspicious breast lesions (Figure 1).
Starting from the importance to simultaneously inves-
tigate multiple biomarkers in different breast diseases
(like atypia and cancer) to avoid pitfalls, shortcomings
and false discovery of candidate biomarkers [17,20], the
multiple combination of well known biomarkers (TF,
uPA and PAI-1) significantly contribute to the improve-
ment of earlier diagnosis and prognosis of BC. So,
Sauter’ study [65] is a promising example of how breast
microenvironment biomarkers (that alone did not reach
the excellence of the clinical/diagnostic/prognostic sig-
nificance in pre and post-menopause, in pre-cancerous
and cancer conditions) may be really useful only through
a combination, providing predictive ability near to 1.0.
“Viribus unitis” (lat. "With united forces"): the intraductal
noninvasive approach of NAF secretome analysis confirms
the importance of considering biomarkers in the breast
microenvironment not individually but in well validated
combinations, to provide more informative diagnostic/
prognostic tests and limiting the biomarkers included in
the “niche unmet needs” [20].
Conclusions
Breast cancer, the major cause of death among women
around the world, is characterized by a high complexity
and not completely understood biological and clinical het-
erogeneity [29]. Also by intricate interrelationships among
the diverse cells composing the solid tumor mass (commit-
ted cancer cells, cancer stem cells, and non-cancer stem
cells and non cancer cells) [4].
Moreover, the altered paracrine/autocrine mechanisms,
physical, biomolecular and hormonal networks in the
breast microenvironment lead to the development and
progression of human BC [37], including the stemming
tumor evolution and the capacity of breast cancer cells
(through also cancer stem cell resistance) to support
tumor maintenance also after an anticancer treatment [4].
The cell heterogeneity of BC reflects the complexity of
the secretome (the mixture of hormones, proteins and
proteinases that cancer mass is able to produce and se-
crete in the breast microenvironment), revealing the
enormous difficulty to find useful and specific biomole-
cules as candidate cancer biomarker(s).
Improving technological methods (e.g., single-cell ana-
lysis) [10] to enable earlier detection and diagnosis of hu-
man BC in conjunction with the discovery and validation
of a powerful combination of biomarkers, may represent
the key tools to obtain a significant impact on morbidity
and mortality in BC.
Figure 1 Nipple Aspirate Fluid (NAF), secreted by non-lactating women into the breast ductal system, represents a mirror of the breast
microenvironment. NAF consists of secreted proteins and cells sloughed from stroma, ductal and lobular epithelium, containing several biomarkers
that may be potentially useful tools. Several studies demonstrated implication of uPA-PAI system (on the left) and TF (Thomsen-Friedenreich) antigen (on
the right) in several steps of breast cancer (BC) progression and metastasis through proteinase cascade activation, cell adhesion and motility. uPA
(urokinase type Plasminogen Activator) is a serine protease whose main function is to catalyze the activation of plasminogen (Plg) into plasmin (Pln), after
binding its receptor, uPAR (urokinase type Plasminogen Activator Receptor). Plasmin is able to degrade Extracellular Matrix (ECM), facilitating the release
of several ECM components and proteolytic enzymes, leading to ECM remodeling and migration of BC cells. The uPA-PAI system activates signaling
pathways promoting adhesion, proliferation and cytoskeletal changes in BC. The uPA physiological inhibition by PAI-1 (Plasminogen Activator Inhibitor 1)
controls the activation of Plg into Pln and ECM degradation, modulating proliferation pathways. TF antigen (or CD 176) is a disaccharide constituted by
the core 1 structure of O-linked mucin type glycans, which in normal cells is masked through glycosylation mechanisms. In tumors, various determinants
can lead to alterations in O-glycosylation biosynthesis machinery, leading to the unmasking of TF antigen. Considering these candidate biomarkers
individually, they provide incomplete prediction accuracy: in fact, uPA alone was predictive of breast disease only in premenopausal women (83–87%). TF
alone was only predictive of breast disease in postmenopausal women (81–83%). It has been demonstrated that when TF+uPA+PAI-1 were combined,
their predictive ability approached 100% allowing an excellent improvement of prediction of atypia or BC disease in women requiring surgery because
of suspicious breast lesions.
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studies into the clinical setting, crucial factors have
to be regarded (e.g., sensitivity and specificity of detec-
tion, ability to carry out quantitative measurements,
standardization of sample collection, validation of the
biomarker assay, clinical qualification of the biomarker,
etc.) [21,24].
In this respect, the analysis of the breast cancer micro-
environment, mirrored by NAF, allows the detection ofalterations in biochemical, morphological and molecular
pathways promoting cancer initiation, progression, invasion
and metastasis, taking into account also the different stem/
non-stem cell composition and interactions in the human
breast microenvironment.
Therefore, analyzing NAF breast fluid proteins and
proteinases (like TF, uPA and PAI) we could obtain
useful insights about mechanisms making breast ductal
cells more prone to morphological and biomolecular
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stem differentiation) [69].
Biomarker studies (including genetic, genomic, gene
expression, proteomic and imaging approaches) may
help the comprehension of disease initiation and pro-
gression, stem repopulation of cancer, prediction of pa-
tient population characteristics, finally improving also
the critical points of drug development, drug efficacy
and drug-induced adverse reactions.
It has been biologically and clinically demonstrated that
individual biomarkers cannot predict or monitor cancer
development/progression. To be highly effective in diag-
nostic/prognostic/clinical approaches it is crucial to com-
bine specific biomolecules to obtain an optimal panel of
biomarkers, which, through a comprehensive biomarker
study registry, may significantly reduce false positives and
hopefully identify promising cancer tests [70].
In this respect, the study recently published in BMC
Cancer on TF, uPA and PAI in NAF samples [65] repre-
sents a shining example of how the combination of more
biomolecules (alone not perfectly accurate) may signifi-
cantly improve the prediction of breast atypia and/or
cancer approaching near 100% accuracy, suggesting that
they may be a useful breast cancer biomarker panel.
Future developments in onco-single-cell-omics [10] will
potentially revolutionize cancer biology and clinical prac-
tice, allowing the identification of an ideal combination of
biomolecules as reliable panel of biomarkers for the detec-
tion, diagnosis and monitoring of breast cancer [71].
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